BRUKER CORP Files 8-K on Results & Regulation FD Disclosure

TL;DR

**Bruker just dropped an 8-K, new financial info or big news coming, watch BRKR!**

AI Summary

Bruker Corporation filed an 8-K on January 8, 2024, to disclose information under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). This filing indicates that the company is providing an update on its financial performance or other material non-public information, likely in preparation for an earnings release or investor call. For investors, this matters because it signals that new financial data or significant company news is being made public, which could influence the stock price (BRKR) depending on the nature of the disclosed results.

Why It Matters

This filing signals that Bruker Corporation is releasing new, potentially market-moving financial information or other material disclosures. Investors should watch for the specific details of these disclosures as they could impact the company's valuation and future outlook.

Risk Assessment

Risk Level: medium — The risk is medium because while the filing itself is procedural, the undisclosed content under Items 2.02 and 7.01 could contain either positive or negative financial news, leading to stock volatility.

Analyst Insight

Investors should monitor Bruker Corporation's (BRKR) news channels closely for the specific disclosures related to 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' that this 8-K foreshadows, as these will contain the actual financial or material information that could impact the stock price.

Key Numbers

• January 8, 2024 — Date of Report (The date of the earliest event reported in this 8-K filing.)
• 000-30833 — Commission File No. (Bruker Corporation's SEC file number, identifying its filings.)
• $0.01 — par value per share (The stated par value of Bruker Corporation's Common Stock.)

Key Players & Entities

• BRUKER CORPORATION (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Bruker Corporation
• 000-30833 (dollar_amount) — Commission File No. for Bruker Corporation
• 04-3110160 (dollar_amount) — I.R.S. Employer Identification No. for Bruker Corporation
• 40 Manning Road Billerica , MA 01821 (company) — principal executive offices address for Bruker Corporation
• 978-663-3660 (dollar_amount) — telephone number for Bruker Corporation
• Common Stock, $0.01 par value per share (company) — title of class of securities registered by Bruker Corporation
• BRKR (company) — trading symbol for Bruker Corporation's common stock
• The Nasdaq Global Select Market (company) — exchange where Bruker Corporation's common stock is registered

Forward-Looking Statements

• Bruker Corporation will release specific financial results or material non-public information shortly after this filing. (BRKR) — high confidence, target: 2024-01-15

FAQ

Key Financial Figures

• $0.01 — nge on Which Registered Common Stock, $0.01 par value per share BRKR The Nasdaq
• $830 million — fourth quarter of 2023 is greater than $830 million including organic revenue growth greate
• $2.94 b — for the full year 2023 is greater than $2.94 billion, including organic revenue growth

Filing Documents

• brkr-20240108.htm (8-K) — 51KB
• 0000950170-24-002823.txt ( ) — 167KB
• brkr-20240108.xsd (EX-101.SCH) — 29KB
• brkr-20240108_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, during its scheduled presentation at the 42nd Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) stated that its current preliminary expectation for revenue for the fourth quarter of 2023 is greater than $830 million including organic revenue growth greater than 12% year-over-year and that fourth quarter 2023 BSI bookings were solid. The Company also provided current preliminary expectation that revenue for the full year 2023 is greater than $2.94 billion, including organic revenue growth greater than 13% year-over-year. The Company also provided preliminary outlook for 2024 for solid, above-market growth in organic revenue, and non-GAAP EPS. A copy of the Company's presentation is available in the Investors section of its website at ir.bruker.com. Because the Company’s financial statements for the fourth quarter and fiscal year ended December 31, 2023 have not yet been finalized or audited, this preliminary statement regarding the Company’s current expectations with respect to its fourth quarter 2023 and full year 2023 revenue are subject to change, and the Company’s actual revenues for these periods may differ materially from these preliminary estimates. Accordingly, you should not place undue reliance on these preliminary estimates.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The information set forth in Item 2.02 of this Current Report is incorporated into this Item 7.01 by reference. The information furnished in Item 2.02 and Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Forward Looking Statements

Forward Looking Statements Any statements contained in this Current Report on Form 8-K that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding management’s current expectations with respect to our fourth quarter 2023 and full year 2023 performance, including our revenue growth, and statements regarding our fiscal year 2024 financial outlook, including our outlook for revenue and organic revenue growth. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to the preliminary nature of the Company’s fourth quarter 2023 and full year 2023 financial information, which is subject to completion of the Company’s year-end-audit, risks and uncertainties relating to COVID-19, the length and severity of any recession and the impact on global economic conditions, the impact of supply chain challenges, including inflationary pressures, the impact of geopolitical tensions and any sanctions, including any reduction in natural gas exports from Russia resulting from its ongoing conflict with Ukraine and resulting market disruptions, such as higher prices for and reduced availability of key metals used in our products, the conflict in Israel, Palestine and surrounding areas and the possible expansion of such conflicts and potential geopolitical consequences, the ongoing tensions between the United States and China, tariff and trade policy changes, and increasing potential of conflict involving countries in Asia that are critical to our supply chain operations, such as Taiwan and China, continued volatility in the capital markets, the impact of increased inte

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRUKER CORPORATION (Registrant) Date: January 8, 2024 By: /s/GERALD N. HERMAN Gerald N. Herman Executive Vice President and Chief Financial Officer 3 -Bruker Confidential-

View Full Filing

View this 8-K filing on SEC EDGAR